Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994 Nov 1, 74(9), 875-883. [PMID]: 7977117.
Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, Hadell K, Olsson AG, Carlson LA. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1993 Feb 25, 71(6), 15B-19B. [PMID]: 8434556.
Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I, Walldius G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol. 1995 Aug, 15(8), 1049-1056. [PMID]: 7977117.